<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00889356</url>
  </required_header>
  <id_info>
    <org_study_id>ZD 002-08</org_study_id>
    <nct_id>NCT00889356</nct_id>
  </id_info>
  <brief_title>Evaluate Efficacy, Tolerability &amp; Safety of Combination of Clindamycin and Ketoconazole for the Treatment of Mixed-Type Vaginosis, Bacterial Vaginosis and Candidiasis</brief_title>
  <official_title>Phase III, Open Label, Randomized, Multicenter Study to Evaluate Efficacy, Tolerability &amp; Safety of Combination of Clindamycin 100mg and Ketoconazole 400mg in Vaginal Capsules, Compared to Combination of Tetracycline 100mg and Amphotericin B 50mg in Vaginal Cream for the Treatment of Bacterial Vaginosis and Candidiasis Isolatedly or in Association (Mixed-Type Vaginosis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zodiac Produtos Farmaceuticos S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zodiac Produtos Farmaceuticos S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the Efficacy, Tolerability &amp; Safety of Combination
      of Clindamycin 100mg and Ketoconazole 400mg in Vaginal Capsules, used for 7 consecutive days
      in patients with Mixed-Type Vaginosis compared to Combination of Tetracycline 100mg and
      Amphotericin B 50mg in Vaginal Cream.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">March 2010</completion_date>
  <primary_completion_date type="Anticipated">March 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy based on cure rate evaluated by clinical and laboratory criteria.</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability based on adverse events reports and patient's information</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety based on adverse events reports and laboratory criterion</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Candidiasis</condition>
  <condition>Bacterial Vaginosis</condition>
  <arm_group>
    <arm_group_label>Clindamycin 100mg and Ketoconazole 400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tetracycline 100mg and Amphotericin B 50mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindamycin 100mg and Ketoconazole 400mg</intervention_name>
    <description>1 vaginal capsule once a day at night</description>
    <arm_group_label>Clindamycin 100mg and Ketoconazole 400mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetracycline 100mg and Amphotericin B 50mg</intervention_name>
    <description>One full applicator, once a day at night</description>
    <arm_group_label>Tetracycline 100mg and Amphotericin B 50mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mixed-type vaginosis

          -  Bacterial vaginosis

          -  Candidiasis

        Exclusion Criteria:

          -  Pregnancy

          -  Vaginal bleeding

          -  History of recurrent vaginosis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rogerio Bonassi Machado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CRM Regional Council of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rogerio Bonassi Machado, MD</last_name>
    <phone>+55 11 4521-6466</phone>
    <email>rogeriobonassi@terra.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paula Fabrini, MD</last_name>
    <phone>+55 11 4521-6466</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vox Femina</name>
      <address>
        <city>Jundia√≠</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rogerio Bonassi Machado, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rogerio Bonassi Machado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2009</study_first_submitted>
  <study_first_submitted_qc>April 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2009</study_first_posted>
  <last_update_submitted>April 27, 2009</last_update_submitted>
  <last_update_submitted_qc>April 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2009</last_update_posted>
  <responsible_party>
    <name_title>Julio Cesar Nophal de Carvalho</name_title>
    <organization>Zodiac Produtos Farmaceuticos</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Vaginal Diseases</mesh_term>
    <mesh_term>Vaginosis, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoconazole</mesh_term>
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Tetracycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

